Calmangafodipir for prevention of oxaliplatin-induced peripheral neuropathy: two placebo-controlled, randomized phase 3 studies (polar-a/polar-m)

HIGHLIGHTS

• who: JNCI Cancer Spectrum ( and colleagues from the DepartmentOdense University, Nagoya, Japan have published the paper: Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M), in the Journal: (JOURNAL) of July/27,/2022
• how: The POLAR program also included Asian and non-Asian patients whereas the PLIANT study was conducted in a predominantly Caucasian population.

SUMMARY

In POLAR-A, patients were randomly assigned 1:1 to receive CaM 5 lmol/kg or placebo (0.9% sodium chloride) as an intravenous infusion . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.